Pentasaccharide and Orgaran^® Arrest, whereas Heparin Delays Thrombus Formation in a Rat Arteriovenous Shunt

Summary

The mode of action of glycosaminoglycans (GAGs) towards thrombus formation in a rat arteriovenous shunt was studied by simultaneous examination of thrombus weight, platelet consumption and thrombin generation during 45 min of blood circulation. A comparison was made between the effects of heparin, the heparinoid Org 10172 (Orgaran^®), and the chemically synthesized methoxy derivative of the antithrombin III binding pentasaccharide fragment of heparin (Org 31540).

All three compounds inhibited thrombus growth by 30% at a dose of 80 anti-Xa U/kg i. v. when assessed after 15 min of circulation through the shunt. In addition, a systemic decrease of 27% of platelet numbers in the placebo group was inhibited by heparin and Orgaran^® with 63% and by pentasaccharide with 48%. At a later stage, after 45 min of circulation, at comparable plasma anti-Xa levels, thrombi which had formed in the presence of Orgaran^® or pentasaccharide, but not in the presence of heparin, became less or non thrombogenic. This non-thrombogenicity was reflected by i) an inhibition of the local deposition of [⁵¹Cr]platelets of 75% with Orgaran^® and of 57% with pentasaccharide, and ii) an inhibition of ex-vivo thrombus-induced thrombin generation in pooled rat plasma of 67% with Orgaran^® and of 52% with pentasaccharide (inhibition compared to placebo).

Although the mechanism of inducing non-thrombogenicity of a (developing) thrombus by Orgaran^® and pentasaccharide requires further investigation, the suppression of the local thrombin generation potency, measured by thrombus-induced thrombin generation in pooled plasma, is much more correlated with thrombus growth than systemic anticoagulant activity. This suppression is likely to be due to the anti-Xa activity, as reflected by the efficacy of the pure Xa inhibiting pentasaccharide. Limitation of thrombus growth adds to the prophylactic perspective of Orgaran^® and pentasaccharide in preventing thrombosis.

• References

• 1 Fareed J, Walenga JM, Kumar A, Rock A. A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Hemostas 1985; 11: 155-175
• 2 Walenga JM, Petitou M, Lormeau JC, Samama M, Fa reed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 1987; 46: 187-198
• 3 Vogel GMT, Meuleman DG, Bourgondien FGM, Hobbelen PMJ. Comparison of two experimental thrombosis models in rats; effects of four glycosaminoglycans. Thromb Res 1989; 54: 399-410
• 4 Umetsu T, Sanai K. Effects of 1-methyl-3-mercapto-5-(3-pyridyl) imidazole (KC6141), an anti-aggregating compound, on experimental thrombosis in rats. Thromb Haemostas 1978; 39: 74-83
• 5 Meuleman DG, Vogel GMT, Van Delft AML. Effects of intraarterial accumulation on blood platelet consumption in rats. Thromb Res 1980; 20: 45-55
• 6 Hobbelen PMJ, Vogel GMT, Meuleman DG. Continuous monitoring of thrombus formation in an arteriovenous shunt with the AIMS-system; effects of heparin, Org 10172 and the “natural” pentasac-charide. Thromb Haemostas 1989; 62: 120
• 7 Teien AN, Lie M. Evaluation of an amidolytic heparin assay method. Increased sensitivity by adding purified anti-thrombin III. Thromb Res 1977; 10: 399-410
• 8 Larsen ML, Abildgaard U, Teien AN, Gjesdal K. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S2238). Thromb Res 1978; 13: 285-288
• 9 Salzman EW, Merill EW. Interaction of blood with artificial surfaces. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman RW, Hirsh H, Marder J, Salzman EW. (eds). Philadelphia, PA: Lippincott; 1982. 1st ed., 931-943
• 10 Salzman EW, Lindon J, McManama G, Ware JA. Role of fibrinogen in activation of platelets by artificial surfaces. Ann NY Acad Sci 1987; 516: 184-195
• 11 Packham MA. The behaviour of platelets at foreign surfaces. Proc Soc Expl Biol Med 1988; 189: 261-274
• 12 Bevers EM, Comfurius P, Van Rijn JLML, Hemker HC, Zwaal RFA. Generation of prothrombin-converting activity and the exposure at the outer surface of platelets. Eur J Biochem 1982; 122: 429-436
• 13 Hemker HC, Béguin SJ. Mode of action of unfractionated and low molecular weight heparins on the generation of thrombin in plasma. Haemostasis 1990; 20: 81-92
• 14 Hubbell JA, McIntire LV. Platelet active concentration profiles near growing thrombi: a mathematical consideration. Biophys J 1986; 50: 937-945
• 15 Wagner WR, Hubbell JA. Local thrombin synthesis and fibrin formation in an in vitro thrombosis model result in platelet recruitment and thrombus stabilization on collagen and heparinized blood. J Lab Clin Med 1990; 116: 636-650
• 16 Béguin SJ, Choay J, Hemker HC. The action of a synthetic pentasaccharide on thrombin generation in whole plasma. Thromb Haemostas 1989; 61: 397-401
• 17 Béguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemostas 1989; 61: 25-29
• 18 Badimon L, Badimon JJ, Lassila R, Heras M, Chesebro JH, Fuster V. Thrombin regulation of platelet interaction with damaged vessel wall and isolated collagen type I at arterial flow conditions in a porcine model: Effects of hirudins, heparin, and calcium chelation. Blood 1991; 78: 423-434
• 19 Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218: 725-732
• 20 Walz DA, Hung GL. In vivo studies on the binding of heparin and its fractions with platelet factor 4. Semin Thromb Hemostas 1985; 11: 40-47
• 21 Hobbelen PMJ, Van Dinther TG, Vogel GMT, Van Boeckel CAA, Moelker HCT, Meuleman DG. Pharmacological profile of the chemically synthesized antithrombin III binding fragment of heparin (pentasaccharide) in rats. Thromb Haemostas 1990; 63: 265-270